La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
Fibroblast Activation Protein: an emerging high-value theranostic target for delivery of payloads STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Fibroblast Activation Protein (FAP) Targeted Therapy: a Competitor Analysis. Fibroblast activation protein (FAP) is selectively expressed in reactive stromal fibroblasts of epithelial cancers,...
Glypican-3 (GPC3): an emerging liver cancer target with opportunities for different effector mechanisms STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis. GPC3, a GPI-anchored cell surface heparan sulfate proteoglycan, is an attractive target for hepatocellular carcinoma...
B7-H3: an emerging solid tumor target with promise for antibody-drug conjugates STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: B7-H3-Targeted Immunotherapy: a Competitor Analysis. B7-H3 is a transmembrane protein that belongs to the B7 family, which also includes PD-L1. B7-H3 is overexpressed in...
STUTTGART, Germany I June 28, 2025 I Vectorized antibodies obtained by in vivo expression of DNA or RNA are an emerging drug modality with potential to overcome several of the limitations of passive immunotherapy with antibodies produced ex vivo. La Merie Publishing released a new report about gene therapy technologies...
The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products STUTTGART, Germany I March 09, 2025 I La Merie Publishing announced the release of its newest biologics market report for the calendar year 2024...
STUTTGART, Germany I February 19, 2025 I La Merie Publishing released its newest report with a landscape description and analysis of PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective as...
STUTTGART, Germany I September 04, 2024 I La Merie Publishing released its newest report with a landscape description and analysis of degrader-antibody conjugate (DAC) stakeholders, platform technologies, development and discovery pipelines and partnering deals from an industry perspective as of September 2024: Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders,...
The report covers 2023 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products STUTTGART, Germany I March 08, 2024 I La Merie Publishing released the new report with sales data of recombinant biologics, biosimilars and novel biologic...
BARCELONA, Spain I March 08, 2023 I La Merie Publishing released the 17th edition of its report series about sales of recombinant biologics. The report 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins...
BARCELONA, Spain I February 07, 2023 I La Merie Publishing released today its newest report entitled “CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing”. This report provides a landscape description and analysis of the emerging technology of Chimeric Antigen Receptor Macrophages (CAR-M) from an...
